GSK seeks EU approval for RSV vaccine for younger adults EU decision on expanded use expected by first half of 2026 June 13 (Reuters) - GSK (GSK.L), opens new tab has applied to the European ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season ...

While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply.

Merck's monoclonal antibody, called clesrovimab and branded as Enflonsia, is the first and only preventive shot that can be administered as a single dose regardless of birth weight in healthy pre ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

Moderna’s RSV shot was the first non-COVID-19 mRNA vaccine to be approved in the United States. The Centers for Disease Control and Prevention’s (CDC) independent vaccine panel, the Advisory ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

A decision by the EU's health regulator on the expanded use of the vaccine is expected in the first half of 2026, the British drugmaker said. ($1 = 0.7387 pounds) ...

FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains by: Nathaniel Weixel, The Hill Posted: Jun 13, 2025 / 03:10 PM EDT Updated: Jun 13, 2025 / 03:10 PM EDT ...

Nation and World News FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains by: Nathaniel Weixel, The Hill Posted: Jun 13, 2025 / 03:09 PM EDT Updated: Jun 13, 2025 / 03:09 PM EDT ...